Side-by-Side Comparison: Semaglutide vs Phentermine
| Feature | Semaglutide | Phentermine |
|---|---|---|
| Mechanism | GLP-1 receptor agonist · hormonal | CNS stimulant · norepinephrine release |
| Average weight loss | 14.9% body weight (STEP-1, 68 weeks) | 3–7% body weight (short-term) |
| Format | Injectable or oral (same price) | Oral tablet only |
| Duration of use | Long-term approved (open-ended) | Short-term approved (typically ≤12 weeks) |
| Price at Tmates | $249/mo (12-mo: $158/mo) | $149/mo |
| Food noise reduction | Strong · key mechanism | Moderate · primarily energy |
| Cardiovascular benefit | SELECT trial: −20% MACE | No CV outcome trial data |
| Best for | Long-term clinically significant loss | Short-term kickstart / budget start |
Bottom Line: Semaglutide wins on long-term results (14.9% vs 3–7% average weight loss), longer approved duration, and breadth of metabolic benefits. Phentermine wins on price ($149 vs $249/mo), speed of effect, and no injections. For patients who can afford semaglutide long-term, the clinical evidence strongly favors it. Phentermine is a valid short-term starting point.
How Each Medication Works
Compounded semaglutide through Tmates weight loss is a GLP-1 receptor agonist — it mimics the gut hormone that signals satiety, slows gastric emptying, and reduces food noise through hypothalamic pathways. The mechanism is hormonal and relatively slow: appetite reduction builds over weeks as blood levels achieve therapeutic concentration. The result is sustained, moderate reduction in caloric intake without constant willpower, backed by 68 weeks of clinical trial data.
Phentermine is a sympathomimetic amine — it triggers norepinephrine release in the CNS, producing a rapid fight-or-flight response that suppresses appetite and increases energy. The effect is felt quickly: most patients notice significant appetite reduction within the first few days. But the mechanism produces rapid tolerance, and phentermine is approved only for short-term use (typically not exceeding 12 weeks) because its CNS stimulant effects diminish with sustained use and the medication has addiction potential at clinical doses.
Weight Loss Results: The Clinical Gap
STEP-1 (NEJM 2021) documented 14.9% average body weight loss at 68 weeks with semaglutide. Clinical studies of phentermine document 3–7% average weight loss over 12-week treatment courses. For a 250-pound patient, semaglutide's average translates to approximately 37 pounds; phentermine's translates to 8–18 pounds. This is a substantial clinical gap that reflects both the difference in mechanism and the difference in approved treatment duration.
It's also worth noting that semaglutide's 14.9% average includes all trial participants including lower-dose earlier in titration. Patients who reach maximum dose (2.4mg) and maintain it for the full trial period often see results exceeding the average. Tirzepatide ($297/mo) produces even greater results at 22.5% average — see the semaglutide vs tirzepatide comparison for full analysis.
When Phentermine Makes Sense
Despite semaglutide's clinical advantage, phentermine through Tmates' program is not without value. For patients where $249/month is genuinely cost-prohibitive in the short term, phentermine at $149/month provides physician-supervised prescription weight loss support at an accessible price. For patients who want to test their response to appetite suppression before committing to a longer GLP-1 program, phentermine offers a lower-cost short-term trial. For patients who cannot or will not self-inject and don't want oral GLP-1, phentermine is a pill-only option. Read: Contrave vs phentermine and Qsymia vs phentermine for further comparison context within the non-GLP-1 category. Explore the full weight loss category.
🏥 Ready to Start Your Treatment?
Get Semaglutide or Phentermine through Tmates — free shipping, licensed physicians, all 50 states.
Get Started with Tmates →